Real-world decisions with real-world data
Discover new insights from our growing RWD cohorts. This expanding data provides deeper understanding and reinforces current treatment approaches in everyday clinical practice.
Arshad Khanani
(Chair)
Robin Hamilton
Nirojini Sivachandran
Paul Mitchell
Thursday, 4th September | 13:30-14:30
Amphitheatre Bordeaux, Level 3
Through our patients' eyes: Patient voices in the era
of continuous drug
delivery for retinal disease
This symposium on continuous drug delivery in retinal diseases will examine remaining unmet patient need, patient selection considerations, and share the latest clinical data from trials of the Port Delivery Platform with ranibizumab (PDS) with a focus on insights from the patient perspective.
Carl Awh
(Chair)
Rosa Dolz-Marco
Matthias Becker
Dante Pieramici
Thursday, 5th September | 9:45-10:45
Amphitheatre Havane, Level 3
The nAMD challenge: Looking beyond VEGF-A inhibition
The nAMD Challenge is on! We'll present the latest clinical and real-world data in nAMD, exploring how dual inhibition is driving drying and durability, all within an engaging game show format.
Frank Holz
(Chair)
Veeral Sheth
Adrian Koh
Aude Couturier
Friday, 5th September | 13:45-14:45
Amphitheatre Bordeaux, Level 3
Advocating for innovative therapies:
Everything you need to know
Explore how Faricimab can optimize clinic flow and capacity. This symposium provides HCPs with the essential knowledge to confidently advocate for first-line access in both private and public practices.
Ian Pearce
(Chair)
Roberto Gallego
Gabriela Grimaldi
Don Husereau
Saturday, 6th September | 10:15-11:15
Amphitheatre Bordeaux, Level 3
The DME challenge: Looking beyond VEGF-A inhibition
The DME Challenge is on! We'll present the latest clinical and real-world data in DME, exploring how dual inhibition is driving drying and durability, all within an engaging game show format.
SriniVas Sadda
(Chair)
Ian Pearce
Stela Vujosevic
Varun Chaudhary
Saturday, 6th September | 13:00-14:00
Amphitheatre Bordeaux, Level 3
FULL PROGRAM coming in August
© 2025 F. Hoffmann-La Roche Ltd M-XX-00020501 | Date of Preparation: July 2025
This website is a global information resource for a public audience, outside of the United States of America and United Kingdom. This website is produced by Roche and is not intended to provide medical advice and/or treatment guidance. The content on this website is non-promotional and does not make specific reference to the availability or the use of a medicine.
This medical-scientific material contains information on therapies*,† that may have not yet been approved for use in your country, including by the European Medicines Agency, and for which no adequate statement on safety and efficacy can be made. This information does not intend to promote the use of products prior to or outside the respective marketing authorisation under drug law.
*Faricimab▼ is approved for the treatment of nAMD, DME and RVO in several countries worldwide, including by the European Medicines Agency. Approval conditions may vary internationally. Status as of August 2024. The full SmPC is available under this link.
▼ Ce médicament fait l’objet d’une surveillance supplémentaire qui permettra l’identification rapide de nouvelles informations relatives à la sécurité. En signalant les effets indésirables, vous contribuez à fournir davantage d’informations sur la sécurité du médicament. This medicinal product is subject to additional monitoring, reporting of suspected adverse reactions associated with this medicine is a priority.
The Port Delivery Platform with Ranibizumab (PDS) is approved in the US. for the treatment of patients with nAMD, DME, and DR. PDS is not authorized in Europe. Status as of June 2025.
Find Us
